Ovarian Cancer

Researchers running clinical should be aware of how these new drugs affect our day-to-day lives — not just in the big ways, but also the small ones that take their toll over the long haul.

Women who face menopause after a cancer diagnosis may be able to manage their symptoms without relying on estrogen-based therapies, although discussing this with a cancer team will help patients find what’s best for them.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.

The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.

I am still here fighting, fighting hard and I will continue to do so to make sure I have more graduations, more weddings, and more everything that I can squeeze into my precious time left here on earth.

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

There are many people in my life who made my cancer experience far easier. I call them my "cancer posse."

Treatment with Gen-1, a novel gene therapy, resulted in a 33% improvement in progression-free survival for patients with advanced ovarian cancer, according to recent study findings.

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.

For patients with advanced epithelial ovarian cancer, there were little — if any — differences in survival outcomes depending on when they received surgery.

The FDA granted a Fast Track designation to ofra-vec plus paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

The season of spring represents new awakenings for me, and this year, I’m determined to bring an air of positivity to my life and my cancer experience.

While a recent health scare ruined a family vacation, I vowed to keep making plans and always look ahead to brighter days.

When caregivers — considered by many to be an essential part of a patient’s care team — have the tools they need to care for themselves and their loved ones, cancer outcomes can be better, too.

The MEK inhibitor trametinib should be considered a new standard of care for patients with a rare subtype of ovarian cancer, explains an expert from The University of Texas MD Anderson Cancer Center.

A patient with ovarian cancer describes how she enrolled in a clinical trial, and how it has given her a renewed sense of hope that she may find a successful treatment option.

From the death of comedian Louie Anderson after he was hospitalized for cancer treatment to former world No.1 tennis player Chris Evert’s ovarian cancer diagnosis, here’s what’s happening in the cancer landscape this week.

After a challenging year due to COVID-19 and rising blood test numbers, a woman living with ovarian cancer shares on what she’s learned and how she’s approaching 2022.

A prostate cancer survivor explains his regret over not pushing his sister to visit the doctor as soon as she showed concerning symptoms, which were eventually revealed to be the stage 4 ovarian cancer that took her life.

Treatment programs that often use neoadjuvant chemotherapy as a strategy may help prolong survival in patients with advanced ovarian cancer compared with those that infrequently used the tactic, which may reassure patients and providers.

Mirvetuximab soravtansine had promising response rates and tolerability in patients with pretreated folate receptor alpha-high platinum-resistant ovarian cancer.

A woman with ovarian cancer explains why she was reluctant to get a port put in and why she ultimately went forward with it. “Somehow, I felt that if I got the port, I was giving in to the cancer,” she writes.